

## SUPPLEMENTARY MATERIAL

### References for Class U studies

### References for chorea

1. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. *Neurology* 2003;61(11):1551--1556 , pmid = 14663041.
2. Landwehrmeyer GB, Dubois B, de Ybenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. *Ann Neurol* 2007;62(3):262--272 , pmid = 17702031.
3. Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. *Mov Disord* 2006;21(4):530--533 , pmid = 16258942.
4. Prundean A, Youssov K, Humbert S, Bonneau D, Verny C. A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. *Mov Disord* 2015;30(2):288--289 , pmid = 25475049.
5. Verny C, Bachoud-Lvi AC, Durr A, et al. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease. *Mov Disord* 2017;32(6):932--936 , pmid = 28436572.
6. Van de Roovaart HJ, Nguyen N, Veenstra TD. Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis. *Pharmaceuticals (Basel)* 2023;16(11).
7. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. *N Engl J Med* 2019;380(24):2307--2316 , pmid = 31059641.
8. de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. *Mov Disord* 2004;19(12):1516--1518 , pmid = 15390067.
9. de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. *Clin Neuropharmacol* 2007;30(1):43--46 , pmid = 17272969.
10. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. *Mov Disord* 2004;19(6):692--695 , pmid = 15197710.
11. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. *Neurology* 2003;60(5):883--884 , pmid = 12629257.

12. Minocycline safety and tolerability in Huntington disease. *Neurology* 2004;63(3):547--549 , pmid = 15304592.
13. Bonelli RM, Hdl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. *Int Clin Psychopharmacol* 2004;19(6):337--342 , pmid = 15486519.
14. A futility study of minocycline in Huntington's disease. *Mov Disord* 2010;25(13):2219--2224 , pmid = 20721920.
15. Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. *J Neural Transm Suppl* 2004(68):117--122 , pmid = 15354397.
16. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. *Parkinsonism Relat Disord* 2007;13(7):453--454 , pmid = 17046312.
17. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. *Bmc Neurology* 2006;6.
18. de Tommaso Ma. Efficacy of levetiracetam in Huntington disease. *Clin Neuropharmacol* 2005;28(6):280--284 , pmid = 16340384.
19. Murman DL, Giordani B, Mellow AM, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. *Neurology* 1997;49(1):153--161 , pmid = 9222184.
20. Ranen NG, Peyser CE, Coyle JT, et al. A controlled trial of idebenone in Huntington's disease. *Mov Disord* 1996;11(5):549--554 , pmid = 8866496.
21. Anderson K. Safety and Tolerability of Nilotinib in Patients with Huntington's Disease. *Movement Disorders* 2022;37.
22. Piolti R, Appollonio I, Perego M, et al. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea. *Eur Neurol* 1995;35(6):344--348 , pmid = 8591802.
23. Underwood BR, Green-Thompson ZW, Pugh PJ, et al. An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. *J Neurol* 2017;264(12):2457-2463.

24. Adanyeguh IM, Rinaldi D, Henry PG, et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. *Neurology* 2015;84(5):490--495 , pmid = 25568297.
25. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. *Movement Disorders* 1996;11(3):273--277.
26. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. *Clin Neuropharmacol* 2010;33(5):260--264 , pmid = 20616707.
27. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2011;10(12):1049--1057 , pmid = 22071279.
28. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. *Mov Disord* 2013;28(10):1407--1415 , pmid = 23450660.
29. Squitieri F, Landwehrmeyer B, Reilmann R, et al. One-year safety and tolerability profile of pridopidine in patients with Huntington disease. *Neurology* 2013;80(12):1086--1094.
30. McGarry A, Kieburtz K, Abler V, et al. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. *J Huntingtons Dis* 2017;6(3):189--199 , pmid = 28826192.
31. Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. *Lancet Neurol* 2019;18(2):165--176 , pmid = 30563778.
32. McGarry A, Auinger P, Kieburtz K, et al. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. *J Huntingtons Dis* 2020;9(2):173--184 , pmid = 32508327.
33. McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. *J Huntingtons Dis* 2020;9(4):371--380 , pmid = 33164941.
34. Furtado S, Sossi V, Hauser RA, et al. Positron emission tomography after fetal transplantation in Huntington's disease. *Ann Neurol* 2005;58(2):331--337 , pmid = 16049929.
35. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients

with Huntington's disease 6 years after surgery: a long-term follow-up study. *Lancet Neurology* 2006;5(4):303--309.

36. Reuter I, Tai YF, Pavese N, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. *J Neurol Neurosurg Psychiatry* 2008;79(8):948--951 , pmid = 18356253.
37. Paganini M, Biggeri A, Romoli AM, et al. Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. *J Neurol Neurosurg Psychiatry* 2014;85(9):974--981 , pmid = 24347577.
38. Macedo J, Pagani E, Wenceslau CV, Ferrara L, Kerkis I. A Phase I Clinical Trial on Intravenous Administration of Immature Human Dental Pulp Stem Cells (Nestacell Hdtm) to Huntington's Disease Patients. *Cytotherapy* 2021;23(4):1.
39. Bachoud-Levi AC, on behalf the Multicentric Intracerebral Grafting in Huntington's Disease G. Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. *Mov Disord* 2020;35(8):1323-1335.
40. Bloch J, Bachoud-Lvi AC, Dglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. *Hum Gene Ther* 2004;15(10):968--975 , pmid = 15585112.
41. Leng TR, Woodward MJ, Stokes MJ, Swan AV, Wareing LA, Baker R. Effects of multisensory stimulation in people with Huntington's disease: a randomized controlled pilot study. *Clin Rehabil* 2003;17(1):30-41.
42. Brusa L, Versace V, Koch G, et al. Improvement of choreic movements by 1 Hz repetitive transcranial magnetic stimulation in Huntington's disease patients. *Ann Neurol* 2005;58(4):655-656.
43. Beste C, Mückschel M, Elben S, et al. Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease. *Brain Struct Funct* 2015;220(4):2441-2448.
44. Delorme C, Rogers A, Lau B, et al. Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns. *J Neurol* 2016;263(2):290-298.
45. Sanrey E, Macioce V, Gonzalez V, et al. Does pallidal neuromodulation influence cognitive decline in Huntington's disease? *J Neurol* 2021;268:613-622.

46. Horisawa S, Kitagawa K, Kawamata T, Taira T. Locomotor recovery of juvenile Huntington's disease treated by Pallidothalamic tractotomy. *Movement Disorders* 2021;36(4):1028-1029.

## References for dystonia

1. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2011;10(12):1049-1057.
2. A randomized, double-blind, placebo-controlled trial of pridoipidine in Huntington's disease. *Mov Disord* 2013;28(10):1407-1415.
3. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. *Ann Pharmacother* 2004;38(7-8):1194-1196.
4. Saft C, von Hein SM, Lücke T, et al. Cannabinoids for Treatment of Dystonia in Huntington's Disease. *J Huntingtons Dis* 2018;7(2):167-173.
5. Ferrea S, Groiss SJ, Elben S, et al. Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data. *J Neurol* 2018;265(7):1573-1579.
6. Zittel S, Tadic V, Moll CKE, et al. Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease. *Parkinsonism Relat Disord* 2018;51:96-100.
7. Kang GA, Heath S, Rothlind J, Starr PA. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. *J Neurol Neurosurg Psychiatry* 2011;82(3):272-277.
8. Velez-Lago FM, Thompson A, Oyama G, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease. *Stereotact Funct Neurosurg* 2013;91(2):129-133.
9. Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. *J Neurosurg* 2014;121(1):114-122.
10. López-Sendón Moreno JL, García-Caldentey J, Regidor I, del Álamo M, García de Yébenes J. A 5-year follow-up of deep brain stimulation in Huntington's disease. *Parkinsonism Relat Disord* 2014;20(2):260-261.

11. Wojtecki L, Groiss SJ, Ferrea S, et al. A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease. *Front Neurol* 2015;6:177.
12. Cubo E, Shannon KM, Penn RD, Kroin JS. Internal globus pallidotomy in dystonia secondary to Huntington's disease. *Mov Disord* 2000;15(6):1248-1251.
13. Bachoud-Lévi AC, Gaura V, Brugières P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. *Lancet Neurol* 2006;5(4):303-309.
14. Bocci T, Baloscio D, Ferrucci R, Sartucci F, Priori A. Cerebellar Direct Current Stimulation (ctDCS) in the Treatment of Huntington's Disease: A Pilot Study and a Short Review of the Literature. *Front Neurol* 2020;11:614717.

### **Reference for Gait and balance**

1. Bonelli RM, Niederwieser G, Lahousen T, Hofmann P. Zotepine in Huntington's disease. *Hum Psychopharmacol* 2003;18(3):227-229.
2. Frattola L, Albiazzati MG, Spano PF, Trabucchi M. Treatment of Huntington's chorea with bromocriptine. *Acta Neurol Scand* 1977;56(1):37-45.
3. Du\* R. Impact of Carylolanemagnolol on Gait and Functional Mobility on Individuals with Huntington's Disease. *Tropical Journal of Pharmaceutical Research* 2015;14 (9):1713-1717.
4. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. *J Neurol Neurosurg Psychiatry* 1984;47(8):848-852.
5. Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. *J Neurol Sci* 2014;347(1-2):219-223.
6. Bonelli RM, Niederwieser G, Tribl GG, Költringer P. High-dose olanzapine in Huntington's disease. *Int Clin Psychopharmacol* 2002;17(2):91-93.
7. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. *J Neurol Neurosurg Psychiatry* 1998;65(4):577-579.
8. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. *Ann Pharmacother* 2004;38(7-8):1194-1196.

### **Reference for Parkinsonism**

1. Fann WE, Gerber CJ, McKenzie GM. Physostigmine in rigid Huntington's disease. *Confin Neurol* 1973;35(5):312-315.
2. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. *Journal of Neurology Neurosurgery and Psychiatry* 1998;65(4):577-579.
3. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. *Annals of Pharmacotherapy* 2004;38(7-8):1194-1196.
4. Salari M, Beladi Moghadam N, Soleimani S, Etemadifar M. Atypical parkinsonism can be a presenting feature of late-onset Huntington's disease. *Clinical Case Reports* 2022;10(7).
5. Pérez-Pérez J, Martínez-Horta S, Carceller M, Pagonabarraga J, Kulisevsky J. Rasagiline for the treatment of Parkinsonism in Huntington's disease. *Mov Disord* 2014;29:S213.
6. Heim B, Bajaj S, De Marzi R, et al. Nabilone in huntington's disease: A case series of five patients. *Journal of Neurology, Neurosurgery and Psychiatry* 2016;87:A103.
7. Jongen PJ, Renier WO, Gabreëls FJ. Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic--rigid form. *Clin Neurol Neurosurg* 1980;82(4):251-261.
8. Bonelli RM, Niederwieser G, Diez J, Gruber A, Költringer P. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. *Clin Neuropharmacol* 2002;25(1):58-60.

## References for Myoclonus

9. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. *BMC neurology* 2006;6:11.
10. Carella F, Scaioli V, Ciano C, Binelli S, Oliva D, Girotti F. ADULT ONSET MYOCLONIC HUNTINGTONS-DISEASE. *Movement Disorders* 1993;8(2):201-205.
11. Vogel CM, Drury I, Terry LC, Young AB. Myoclonus in adult Huntington's disease. *Ann Neurol* 1991;29(2):213-215.
12. Previdi P, Borgonovi R. Myoclonus and Huntington's chorea: description of a case. *Italian journal of neurological sciences* 1980;1(3):189-191.
13. Aoba S, Komiyama A, Yamada H, Hasegawa O. [Action myoclonus in adult

Huntington's disease]. *Rinsho Shinkeigaku* 1992;32(7):739-742.

14. Funakawa I, Kimura K, Jinnai K. [Cortical reflex myoclonus in adult onset Huntington's disease]. *Rinsho Shinkeigaku* 2004;44(9):639-642.
15. Thompson PD, Bhatia KP, Brown P, et al. CORTICAL MYOCLONUS IN HUNTINGTONS-DISEASE. *Movement Disorders* 1994;9(6):633-641.
16. Kereshi S, Schlagenhauff RE, Richardson KS. Myoclonic and major seizures in early adult Huntington's chorea: Case-report and electro-clinical findings. *Clinical EEG Electroencephalography* 1980;11(2):44-47.

### **References for Apathy**

1. Pérez-Pérez J, Martínez-Horta S, Pagonabarraga J, Carceller M, Kulisevsky J. Rasagiline for the treatment of parkinsonism in Huntington's disease. *Parkinsonism Relat Disord* 2015;21(3):340-342.
2. Molnar MJ, Molnar V, Fedor M, et al. Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment. *Frontiers in Psychiatry* 2022;12.
3. Saft C, von Hein SM, Lücke T, et al. Cannabinoids for Treatment of Dystonia in Huntington's Disease. *J Huntingtons Dis* 2018;7(2):167-173.
4. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. *Ann Clin Psychiatry* 2008;20(1):1-3.
5. Trinkler I, Chéhère P, Salgues J, et al. Contemporary Dance Practice Improves Motor Function and Body Representation in Huntington's Disease: A Pilot Study. *J Huntingtons Dis* 2019;8(1):97-110.
6. Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study. *Front Behav Neurosci* 2022;16:931636.

### **References for Depression**

1. Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. *Int Clin Psychopharmacol* 2010;25(1):46-50.
2. Molnar MJ, Molnar V, Fedor M, et al. Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment. *Front Psychiatry* 2021;12:825532.



3. Shen YC. Lamotrigine in motor and mood symptoms of Huntington's disease. *World J Biol Psychiatry* 2008;9(2):147-149.
4. Adrissi J, Nadkarni N, Gausche E, Bega D. Electroconvulsive Therapy (ECT) for the Treatment of Refractory Depression in Huntington's Disease Patients: A Case Series. *Neurology* 2019;92(15):2.
5. Mowafi W, Millard J. Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington's disease: case report and review of the literature. *BJPsych bulletin* 2021;45(2):97-104.
6. Davis M, Phillips A, Tendler A, Oberdeck A. Deep rTMS for Neuropsychiatric Symptoms of Huntington's Disease: Case Report. *Brain Stimulation* 2016;9(6):960-961.
7. Groiss SJ, Netz J, Lange HW, Buetefisch CM. Frequency dependent effects of rTMS on motor and cognitive functions in Huntington's disease. *Basal Ganglia* 2012;2(1):41-48.
8. Vieira RT, Inácio DM, de Sousa Fonseca LP, Caixeta L. Physical therapy in huntington's disease: Report of cases. *Revista Neurociencias* 2011;19(3):504-511.
9. Thompson JA, Cruickshank TM, Penailillo LE, et al. The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. *European Journal of Neurology* 2013;20(9):1325--1329.

### **References for Suicidal idea or attempt**

1. Bonelli RM. Mirtazapine in suicidal Huntington's disease. *Ann Pharmacother* 2003;37(3):452.
2. Raja M, Soleti F, Bentivoglio AR. Lithium treatment in patients with Huntington disease and suicidal behavior. *J Clin Psychopharmacol* 2013;33(6):819-821.
3. Grabski B, Siwek M, Dudek D, Jaeschke R, Banaszkiwicz K. [Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report]. *Psychiatr Pol* 2012;46(4):665-675.
4. Drazinic CM, Hennig BL, Fitzpatrick MJN, Shea WP. Ect maintenance treatment for medication-refractory depression, persistent suicidal ideation, and obsessions with contamination in advanced Huntington's disease. *Clinical Genetics* 2011;80:45.

5. Adrissi J, Nadkarni N, Bega D. Evaluating the impact of electroconvulsive therapy (ECT) on refractory depression in Huntington disease: A case series. *Neurotherapeutics* 2018;15(4):1168.
6. Hubers AA, Hamming A, Giltay EJ, et al. Suicidality in Huntington's Disease: A Qualitative Study on Coping Styles and Support Strategies. *J Huntingtons Dis* 2016;5(2):185-198.

### **References for Obsession**

1. Chari S, Quraishi SH, Jain AK. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. *Pharmacopsychiatry* 2003;36(1):41-43.
2. Patzold T, Brüne M. Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline. *Neuropsychiatry Neuropsychol Behav Neurol* 2002;15(3):216-219.
3. De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington's disease. *Psychopharmacology (Berl)* 2001;153(2):264-266.
4. Javelot H, Meyer M, Frismand S, Hingray C. Benefit of long-acting paliperidone in Huntington's disease: a case report. *Int Clin Psychopharmacol* 2021;36(2):101-103.
5. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. *Psychosomatics* 2006;47(1):70-72.
6. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001;14(1):69-72.

### **References for Irritability**

1. Heim B, Bajaj S, De Marzi R, et al. Nabilone in huntington's disease: A case series of five patients. *Journal of Neurology, Neurosurgery and Psychiatry* 2016;87
2. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. *Ann Clin Psychiatry* 2008;20(1):1-3.
3. Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. *Am J Psychiatry* 1994;151(7):1097.
4. Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. *Psychosomatics* 1993;34(5):460-461.

5. Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to huntington's disease and other neurological disorders. *Psychosomatics* 1997;38(4):389-391.
6. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. *J Neuropsychiatry Clin Neurosci* 2006;18(4):553-554.
7. Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington's disease. *J Clin Psychopharmacol* 2001;21(2):245-246.
8. Grove VE, Jr, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. *N Engl J Med* 2000;343(13):973-974.
9. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001;14(1):69-72.
10. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. *Eur J Neurol* 2002;9(2):182-183.
11. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. *J Neuropsychiatry Clin Neurosci* 1996;8(3):338-340.
12. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. *Psychosomatics* 2006;47(1):70-72.
13. Shen YC. Lamotrigine in motor and mood symptoms of Huntington's disease. *World J Biol Psychiatry* 2008;9(2):147-149.
14. Stewart JT, Mounts ML, Clark RL, Jr. Aggressive behavior in Huntington's disease: treatment with propranolol. *J Clin Psychiatry* 1987;48(3):106-108.
15. Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. *J Clin Psychiatry* 1987;48(9):385-386.

### **References for Anxiety**

1. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001;14(1):69-72.
2. Silver A. Cognitive-behavioural therapy with a Huntington's gene positive patient. *Patient Educ Couns* 2003;49(2):133-138.
3. Bartlett DM, Dominguez DJ, Lazar AS, et al. Multidisciplinary rehabilitation reduces

hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study. *J Neurol Sci* 2020;408:116522.

4. Ringqvist K, Borg K, Möller MC. Tolerability and psychological effects of a multimodal day-care rehabilitation program for persons with Huntington's disease. *J Rehabil Med*
5. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. *Ann Clin Psychiatry* 2008;20(1):1-3.

### **References for Sexual dysfunction**

1. Jhanjee A, Anand KS, Bajaj BK. Hypersexual features in huntington's disease. *Singapore Medical Journal* 2011;52(6):131-133.
2. Janati A. Kluver-Bucy syndrome in Huntington's chorea. *J Nerv Ment Dis* 1985;173(10):632-635.
3. Rich SS, Ovsiew F. Leuprolide acetate for exhibitionism in Huntington's disease. *Mov Disord* 1994;9(3):353-357.
4. Tavares A, Volpe FM. Cyproterone for treatment of hypersexuality in an elderly Huntington's disease patient. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32(8):1994-1995.
5. Blass DM, Steinberg M, Leroi I, Lyketsos CG. Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. *Am J Psychiatry* 2001;158(12):1966-1972.

### **References for Dementia**

1. Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study. *Front Behav Neurosci* 2022;16:931636.
2. Molnar MJ, Molnar V, Fedor M, et al. Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment. *Front Psychiatry* 2021;12:825532.
3. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. *Parkinsonism Relat Disord* 2007;13(7):453--454 , pmid = 17046312.

## References for Psychosis and hallucination

1. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. *Ann Clin Psychiatry* 2008;20(1):1-3.
2. Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. *Am J Psychiatry* 2008;165(9):1207-1208.
3. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. *Eur J Neurol* 2002;9(2):182-183.
4. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. *Am J Geriatr Psychiatry* 1998;6(4):347-349.
5. Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. *J Natl Med Assoc* 2006;98(8):1353-1355.
6. Ding J, Gadit AM. Psychosis with Huntington's disease: role of antipsychotic medications. *BMJ Case Rep* 2014;2014.
7. Tuman TC, Kayka N, Eroglu T, Yildirim O. Psychosis in huntington's disease: A case report. *Klinik Psikofarmakoloji Bulteni* 2013;23.
8. Trillo L, Ortiz EL, Cunningham M. Psychosis in a patient with huntington's disease without familial diagnosis. *Journal of Neuropsychiatry and Clinical Neurosciences* 2012;24(2):20.
9. Yeo K, Gupta M, Correll CU. Huntington's Disease With Psychotic Features. *Primary Care Companion for CNS Disorders* 2021;23(4).
10. Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. *J Neuropsychiatry Clin Neurosci* 2010;22(3):352c e354-352 e355.
11. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to huntington's disease: a case report. *Can J Psychiatry* 2004;49(6):413.
12. Edlinger M, Seppi K, Fleischhacker W, Hofer A. Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. *Int Clin Psychopharmacol* 2013;28(4):214-216.
13. Bampton TJ, Hack D, Galletly CA. Clozapine treatment for Huntington's disease psychosis.

Australian and New Zealand Journal of Psychiatry 2022;56(2):200.

14. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. *Neurology* 1991;41(1):156.
15. Majothi N, Lee HY, Nagarajan P, Vutla R. Treatment of psychosis in Huntington's disease with clozapine. *Progress in Neurology and Psychiatry* 2020;24(2):14-16.
16. Şengül CB, Hancı E. A case of Huntington's disease presenting with psychotic features. *Dusunen Adam* 2014.
17. Nakano T, Ono S, Yamaguchi J, et al. Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington's disease. *Journal of Neurology* 2013;260(1):312-314.
18. Magid M, Trevino K, Reid WH, Jalalat S, Husain MM, Kahn DA. Emergency ECT in an incapacitated, medically compromised patient with Huntington's disease. *Journal of Psychiatric Practice* 2014;20(6):470-475.
19. Shah RP, Alluri V, Sharma S. Treatment of agitation in huntington's disease with electroconvulsive therapy. *The Journal of Neuropsychiatry and Clinical Neurosciences* 2017;29(3):293-294.
20. Adrissi J, Nadkarni NA, Gausche E, Bega D. Electroconvulsive therapy (ECT) for refractory psychiatric symptoms in Huntington's disease: a case series and review of the literature. *Journal of Huntington's Disease* 2019;8(3):291-300.
21. Mowafi W, Millard J. Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington's disease: case report and review of the literature. *BJPsych bulletin* 2021;45(2):97-104.
22. Evans DL, Pedersen CA, Tancer ME. ECT in the Treatment of Organic Psychosis in Huntington's Disease. *Convuls Ther* 1987;3(2):145-150.
23. Cusin C, Franco FB, Fernandez-Robles C, DuBois CM, Welch CA. Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. *General hospital psychiatry* 2013;35(6):678. e673-678. e675.

## **References for Sleep disturbance**

1. Bartlett DM, Dominguez DJ, Lazar AS, et al. Multidisciplinary rehabilitation reduces

hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study. *J Neurol Sci* 2020;408:116522.

2. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. *Psychosomatics* 2006;47(1):70-72.
3. Banno K, Hobson DE, Kryger MH. Long-term treatment of sleep breathing disorder in a patient with Huntington's disease. *Parkinsonism Relat Disord* 2005;11(4):261-264.
4. References for Weight loss
5. Drymiotis A, Korenyi C, Whittier JR. Mesoridazine in Huntington's disease (chorea): effect on weight, dyskinesia, and mental function. *Current Therapeutic Research - Clinical and Experimental* 1976;20(3):300-307.
6. Konvalinkova R, Dusek P, Doleckova K, Uhrova T, Roth J, Klempir J. Does the risperidone influence weight in Huntington's disease? *Journal of Neurology, Neurosurgery and Psychiatry* 2018;89.
7. Ciancarelli I, Morone G, Iosa M, et al. Rehabilitation outcomes in Huntington disease patients with low body mass index. *J Musculoskelet Neuronal Interact* 2022;22(1):79-86.

## **References for Dysphagia**

1. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. *Neuropsychiatry Neuropsychol Behav Neurol* 2001;14(1):69-72.
2. Reyes A, Cruickshank T, Nosaka K, Ziman M. Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: a pilot randomised controlled trial. *Clin Rehabil* 2015;29(10):961-973.
3. Hunt VP, Walker FO. Dysphagia in Huntington's disease. *J Neurosci Nurs* 1989;21(2):92-95.
4. Kagel MC, Leopold NA. Dysphagia in Huntington's disease: a 16-year retrospective. *Dysphagia* 1992;7(2):106-114.
5. Giddens CL, Coleman AE, Adams CM. A Home Program of Speech Therapy in Huntington's Disease. *Journal of Medical Speech-Language Pathology* 2010;18(2):1-11.